The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures

• Autors principals: Evelien Moorkens (Autor), Brian Godman (Autor), Isabelle Huys (Autor), Iris Hoxha (Autor), Admir Malaj (Autor), Simon Keuerleber (Autor), Silvia Stockinger (Autor), Sarah Mörtenhuber (Autor), Maria Dimitrova (Autor), Konstantin Tachkov (Autor), Luka Vončina (Autor), Vera Vlahović Palčevski (Autor), Gnosia Achniotou (Autor), Juraj Slabý (Autor), Leona Popelková (Autor), Kateřina Kohoutová (Autor), Dorthe Bartels (Autor), Ott Laius (Autor), Jaana E. Martikainen (Autor), Gisbert W. Selke (Autor), Vasileios Kourafalos (Autor), Einar Magnússon (Autor), Rannveig Einarsdóttir (Autor), Roisín Adams (Autor), Roberta Joppi (Autor), Eleonora Allocati (Autor), Arianit Jakupi (Autor), Anita Viksna (Autor), Ieva Greičiūtė-Kuprijanov (Autor), Patricia Vella Bonanno (Autor), Vincent Suttorp (Autor), Øyvind Melien (Autor), Robert Plisko (Autor), Ileana Mardare (Autor), Dmitry Meshkov (Autor), Tanja Novakovic (Autor), Jurij Fürst (Autor), Corinne Zara (Autor), Vanda Marković-Peković (Autor), Nataša Grubiša (Autor), Gustaf Befrits (Autor), Robert Puckett (Autor), Arnold G. Vulto (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry.Objectives: The aim of this paper is to provide a European overview of (list...